243 related articles for article (PubMed ID: 21994958)
1. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).
Schafer AL; Sellmeyer DE; Schwartz AV; Rosen CJ; Vittinghoff E; Palermo L; Bilezikian JP; Shoback DM; Black DM
J Clin Endocrinol Metab; 2011 Dec; 96(12):E1982-9. PubMed ID: 21994958
[TBL] [Abstract][Full Text] [Related]
2. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Aonuma H; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
Tohoku J Exp Med; 2009 Jul; 218(3):201-5. PubMed ID: 19561390
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism.
Harsløf T; Sikjær T; Sørensen L; Pedersen SB; Mosekilde L; Langdahl BL; Rejnmark L
J Clin Endocrinol Metab; 2015 Jul; 100(7):2758-62. PubMed ID: 25955226
[TBL] [Abstract][Full Text] [Related]
4. Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Mokuda S; Okuda Y; Onishi M; Sawada N; Matoba K; Yamada A; Jouyama K; Takasugi K
J Endocrinol Invest; 2012 Jul; 35(7):661-4. PubMed ID: 21970822
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Sebastián-Ochoa A; Fernández-García D; Reyes-García R; Mezquita-Raya P; Rozas-Moreno P; Alonso-Garcia G; Muñoz-Torres M
Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
[TBL] [Abstract][Full Text] [Related]
7. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
[TBL] [Abstract][Full Text] [Related]
8. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Kasukawa Y; Miyakoshi N; Ebina T; Aizawa T; Hongo M; Nozaka K; Ishikawa Y; Saito H; Chida S; Shimada Y
J Bone Miner Metab; 2014 May; 32(3):290-7. PubMed ID: 23846118
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk Between Bone and Fat Tissue: Associations Between Vitamin D, Osteocalcin, Adipokines, and Markers of Glucose Metabolism Among Adolescents.
Giudici KV; Fisberg RM; Marchioni DML; Peters BSE; Martini LA
J Am Coll Nutr; 2017; 36(4):273-280. PubMed ID: 28443718
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K nutritional status and undercarboxylated osteocalcin in postmenopausal osteoporotic women treated with bisphosphonates.
Iwamoto J; Takada T; Sato Y
Asia Pac J Clin Nutr; 2014; 23(2):256-62. PubMed ID: 24901095
[TBL] [Abstract][Full Text] [Related]
11. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus.
Kanazawa I; Yamaguchi T; Yamauchi M; Yamamoto M; Kurioka S; Yano S; Sugimoto T
Osteoporos Int; 2011 Jan; 22(1):187-94. PubMed ID: 20165834
[TBL] [Abstract][Full Text] [Related]
12. Association of vitamin K status with adiponectin and body composition in healthy subjects: uncarboxylated osteocalcin is not associated with fat mass and body weight.
Knapen MH; Schurgers LJ; Shearer MJ; Newman P; Theuwissen E; Vermeer C
Br J Nutr; 2012 Sep; 108(6):1017-24. PubMed ID: 22136751
[TBL] [Abstract][Full Text] [Related]
13. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
14. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
15. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
Piemonte S; Romagnoli E; Bratengeier C; Woloszczuk W; Tancredi A; Pepe J; Cipriani C; Minisola S
J Endocrinol Invest; 2012 Oct; 35(9):866-8. PubMed ID: 22842667
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
17. Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.
Tang Y; Xia H; Kang L; Sun Q; Su Z; Hao C; Xue Y
Med Sci Monit; 2019 Jan; 25():259-268. PubMed ID: 30620727
[TBL] [Abstract][Full Text] [Related]
18. Are Bisphosphonates Associated with Adverse Metabolic and Cognitive Effects? A Study in Intact Rats and Rats Fed High-Fat High-Fructose Diet.
Gancheva S; Zhelyazkova-Savova M
Calcif Tissue Int; 2020 Jul; 107(1):41-51. PubMed ID: 32211934
[TBL] [Abstract][Full Text] [Related]
19. Association between osteocalcin and metabolic syndrome in postmenopausal women.
Lee SW; Jo HH; Kim MR; Kim JH; You YO
Arch Gynecol Obstet; 2015 Sep; 292(3):673-81. PubMed ID: 25716667
[TBL] [Abstract][Full Text] [Related]
20. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
